Morning, Monday, 22nd February 2027
Online
This conference will examine next steps for the life sciences industry in the UK in the context of early implementation of the Life Sciences Sector Plan. Planned areas for discussion include long-term competitiveness and investment, regulation, clinical research and health-data infrastructure, NHS evaluation and adoption of innovation, and regional growth and workforce development.
It will bring together stakeholders and policymakers to assess progress following publication of Life Sciences Sector Plan: One Year On, the Life Sciences Competitiveness Indicators 2026 and the Life Sciences Jobs Plan, alongside the AI Adoption Plan: Life Sciences. Delegates will consider what delivery to date indicates about the effectiveness and coherence of current interventions, in the context of the amended Clinical Trials Regulations, development of the Health Data Research Service and wider reforms to medicines and HealthTech evaluation and access.
Investment, regional growth & workforce
The planned agenda will examine priorities for translating the UK’s research strengths into sustained commercial growth across a wider range of regions. Delegates will consider the conditions needed for emerging and established companies to invest, expand and retain activity in the UK, and the role of regional partnerships in strengthening connections between research assets, business investment and employment. Discussion will assess progress in implementing the Life Sciences Jobs Plan and its potential to address the specialist workforce constraints that limit company growth and regional development, alongside how progress should be measured against trends in company growth and retention, inward investment, exports and high-value employment.
Clinical research, health data & NHS adoption
Further discussion will assess how current reforms to clinical research, health data and regulation are operating in practice and what will be needed to support a more coherent route from scientific development to patient access. Delegates will consider priorities for implementation of the clinical-trials reforms and development of the Health Data Research Service to operate effectively, including the future relationship between industry, regulators, the NHS and research organisations. The agenda will also consider how evidence, evaluation and procurement processes can best support responsible development and more consistent adoption of innovative and AI-enabled products across the NHS.
Overall areas for discussion include:
- Sector Plan delivery: early progress and priorities for the next phase of implementation
- investment & growth: conditions for companies to scale, invest and retain activity in the UK - access to finance, commercial certainty and regional growth
- pricing, reimbursement & procurement: implications for competitiveness, investment and patient access
- manufacturing & skills: domestic capability, supply chain resilience and delivery of the Life Sciences Jobs Plan
- clinical research: implementation of the amended regulations - trial set-up, recruitment, capacity and consistency across the NHS
- health data & AI: development of the Health Data Research Service - access, governance, public confidence and responsible use
- regulation & evaluation: alignment between MHRA, NICE and NHS requirements - including for AI-enabled and adaptive products
- NHS adoption: reducing duplication and variation - evidence, procurement, value and more consistent uptake of innovation